« Zurück
Home /
L-NAME (hydrochloride)

L-NAME (hydrochloride)

ArtNr	HY-18729A-500mg
Hersteller	MedChem Express
CAS-Nr.	51298-62-5
Menge	500 mg
Quantity options	100 mg 10 g 10 mM/1 mL 1 g 500 mg 5 g
Kategorie	Metabolism Cholesterol & Lipid Metabolism Enzymes Other Fatty Acid Enzymes Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.70
Formula	C7H16ClN5O4
Citations	[1]Pfeiffer S, et al. Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement forbioactivation to the free acid, NG-nitro-L-arginine. Br J Pharmacol. 1996 Jul;118(6):1433-40. [2]Kopincová J, et al. L-NAME in the cardiovascular system - nitric oxide synthase activator? Pharmacol Rep. 2012;64(3):511-20. [3]Lo HC, et al. The Nitric Oxide Synthase Inhibitor NG-Nitro-L-Arginine Methyl Ester Diminishes the Immunomodulatory Effects of Parental Arginine in Rats with Subacute Peritonitis. PLoSOne. 2016 Mar 23;11(3):e0151973. [4]Luo H, et al. Effect of nitric oxide synthase inhibitor L-NAME on fear extinction in rats: a task-dependent effect. Neurosci Lett. 2014 Jun 20;572:13-8. [5]Ocsan RJ, et al. Chronic NG-nitro-l-arginine methyl ester (L-NAME) administration in C57BL/6J mice induces a sustained decrease in c-kit positive cells during development of cardiac hypertrophy. J Physiol Pharmacol. 2013 Dec;64(6):727-36. [6]V A Peotta, et al. Cardiovascular neural reflexes in L-NAME-induced hypertension in mice. Hypertension. 2001, 38, 3. [7]Xiaofei Li, et al. Fucoidan from Undaria pinnatifida prevents vascular dysfunction through PI3K/Akt/eNOS-dependent mechanisms in the l-NAME-induced hypertensive rat model. Food Funct. 2016, 7, 5. Adv Sci (Weinh). 2024 Apr 3:e2309002. Arterioscler Thromb Vasc Biol. 2020 Jul;40(7):1705-1721. Bioengineered. 2022 Jan;13(1):1320-1334. Biomed Pharmacother. 2019 Jul;115:108934. Biomed Pharmacother. 2023 Mar 13;161:114484. Biomed Res Int. 2021 May 15. bioRxiv. 2023 Dec 4. bioRxiv. 2023 Nov 1. BMC Nephrol. 2024 Jul 15;25(1):226. Bosn J Basic Med Sci. 2017 May 20;17(2):132-137. Cancer Metab. 2024 May 17;12(1):14. Cancer Res. 2024 Mar 19. Cardiovasc Diabetol. 2024 May 9;23(1):164. Cell Commun Signal. 2021 Mar 18;19(1):35. Evid Based Complement Alternat Med. 2020 Mar 10;2020:3524641. Exp Ther Med. 2018 Aug;16(2):1079-1086. FASEB J. 2024 Jul 31;38(14):e23844. Free Radic Biol Med. 2024 Sep 13:S0891-5849(24)00659-2. Front Cardiovasc Med. 2021 Apr 13;8:654254. Front Med. 2021 Apr 13;8:634882. Hum Gene Ther. 2022 Nov 14. Insect Mol Biol. 2024 Jan 5. Int Immunopharmacol. 2023 Dec 21:127:111313. Int J Immunopathol Pharmacol. Jan-Dec 2022;36:3946320221111117. Int J Mol Med. 2024 Aug;54(2):67. Int J Mol Sci. 2023 Mar 7. J Cardiovasc Transl Res. 2024 Jul 9. J Cell Mol Med. 2024 Apr;28(8):1-11. J Ethnopharmacol. 2022 Jun 17;115476. J Extracell Vesicles. 2023 May;12(5):e12328. JCI Insight. 2021 Sep 22;6(18):e133690. Mediat Inflamm. 2019 Oct 7;2019:6168340. Mediat Inflamm. 2020 Oct 24;2020:1649453. Microvasc Res. 2023 Mar 22;148:104531. Mol Cell Probes. 2023 Feb 2;67:101896. Nutrients. 2022, 14(23), 5025 PeerJ. 2023 May 25. Phytomedicine. 6 June 2022, 154242. Placenta. 12 November 2021. Placenta. 2021 Feb 11. Research Square Preprint. 2021 Feb. Research Square Preprint. 2022 May. Research Square Preprint. 2023 May 30. Toxicol Appl Pharmacol. 2019 Mar 1;366:83-95. Vet Microbiol. 19 July 2022, 109514. Biomed Pharmacother. 2020 Aug;128:110240. Cell Tissue Res. 2022 Jan 29.
Smiles	N[C@@H](CCCNC(N[N+]([O-])=O)=N)C(OC)=O.[H]Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	NG-Nitroarginine methyl ester hydrochloride
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	NO Synthase
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, sealed storage, away from moisture)
Molecular Weight	269.69
Product Description	L-NAME hydrochloride inhibits NOS with an IC50 of 70 μM. L-NAME is a precursor to NOS inhibitor L-NOARG which has an IC50 value of 1.4 μM.
Manufacturer - Research Area	Cancer
Solubility	H2O : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Immunology/Inflammation
Clinical information	Phase 3

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkdatenblatt anfordern

HY-18729A-500mg-safety-datasheet.pdf